MRKPDUFA
WELIREG/Belzutifan (MK-6482) + LENVIMA/Lenvatinib (E7080) (HIF-2α Combo)
Advanced Clear Cell Renal Cell Carcinoma After PD-1/PD-L1 Therapy
Approval decisionFDA regulatory calendar
Track FDA action dates and advisory committee meetings by month. Each event links to its company, drug, indication and source-backed research record.
FDA regulatory calendar
Advanced Clear Cell Renal Cell Carcinoma After PD-1/PD-L1 Therapy
Approval decisionUse the monthly FDA calendar to review PDUFA target dates and advisory committee meetings, then open each event for drug, company, indication and source context.